Denali Therapeutics (NASDAQ:DNLI) Price Target Lowered to $42.00 at Oppenheimer

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) had its price objective reduced by Oppenheimer from $50.00 to $42.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has an "outperform" rating on the stock. Oppenheimer's target price points to a potential upside of 158.14% from the company's previous close.

A number of other equities analysts have also recently issued reports on DNLI. William Blair reaffirmed an "outperform" rating on shares of Denali Therapeutics in a research note on Friday, February 28th. JPMorgan Chase & Co. reduced their price target on Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating on the stock in a research report on Tuesday, January 7th. Deutsche Bank Aktiengesellschaft initiated coverage on Denali Therapeutics in a report on Tuesday, February 11th. They issued a "buy" rating and a $31.00 price objective for the company. HC Wainwright raised their target price on Denali Therapeutics from $80.00 to $87.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Finally, Baird R W upgraded Denali Therapeutics to a "strong-buy" rating in a research report on Tuesday, January 7th. Two investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $37.57.

Remove Ads

Denali Therapeutics Trading Down 0.2 %

Shares of DNLI traded down $0.03 during trading hours on Monday, hitting $16.27. 1,714,890 shares of the stock traded hands, compared to its average volume of 1,005,122. The business has a fifty day moving average of $20.98 and a 200-day moving average of $24.41. The firm has a market capitalization of $2.34 billion, a PE ratio of -5.89 and a beta of 1.43. Denali Therapeutics has a 1-year low of $14.01 and a 1-year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.75) by $0.08. As a group, equities research analysts expect that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

Insider Activity at Denali Therapeutics

In other Denali Therapeutics news, CEO Ryan J. Watts sold 29,266 shares of Denali Therapeutics stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $20.22, for a total value of $591,758.52. Following the sale, the chief executive officer now owns 260,721 shares of the company's stock, valued at $5,271,778.62. This trade represents a 10.09 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Carole Ho sold 12,255 shares of the company's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $20.22, for a total value of $247,796.10. Following the transaction, the insider now directly owns 178,580 shares of the company's stock, valued at $3,610,887.60. This represents a 6.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 47,940 shares of company stock valued at $973,442. 7.90% of the stock is owned by corporate insiders.

Institutional Trading of Denali Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in DNLI. Mirae Asset Global Investments Co. Ltd. grew its position in Denali Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company's stock valued at $152,000 after purchasing an additional 920 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of Denali Therapeutics by 13.8% during the 3rd quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company's stock worth $36,076,000 after buying an additional 149,939 shares during the last quarter. AIA Group Ltd grew its holdings in shares of Denali Therapeutics by 7.9% in the 3rd quarter. AIA Group Ltd now owns 74,815 shares of the company's stock valued at $2,179,000 after acquiring an additional 5,471 shares in the last quarter. Assetmark Inc. increased its position in shares of Denali Therapeutics by 18.0% in the third quarter. Assetmark Inc. now owns 3,808 shares of the company's stock valued at $111,000 after acquiring an additional 580 shares during the last quarter. Finally, Victory Capital Management Inc. raised its holdings in Denali Therapeutics by 163.7% during the third quarter. Victory Capital Management Inc. now owns 39,900 shares of the company's stock worth $1,162,000 after acquiring an additional 24,767 shares in the last quarter. 92.92% of the stock is currently owned by institutional investors and hedge funds.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.